Outset Medical Inc (OM)

$0.62

+0.04

(+6.35%)▲

Market is closed - opens 7 PM, 07 Oct 2024

Performance

  • $0.57
    $0.63
    $0.62
    downward going graph

    8.11%

    Downside

    Day's Volatility :9.57%

    Upside

    1.59%

    downward going graph
  • $0.44
    $10.06
    $0.62
    downward going graph

    29.84%

    Downside

    52 Weeks Volatility :95.68%

    Upside

    93.84%

    downward going graph

Returns

PeriodOutset Medical IncSector (Health Care)Index (Russel 2000)
3 Months
-82.7%
5.0%
0.0%
6 Months
-75.45%
5.9%
0.0%
1 Year
-93.5%
16.6%
0.0%
3 Years
-98.75%
18.9%
-21.4%

Highlights

Market Capitalization
32.3M
Book Value
$1.32
Earnings Per Share (EPS)
-3.14
Wall Street Target Price
3.63
Profit Margin
-136.72%
Operating Margin TTM
-112.33%
Return On Assets TTM
-28.99%
Return On Equity TTM
-126.48%
Revenue TTM
116.4M
Revenue Per Share TTM
2.29
Quarterly Revenue Growth YOY
-24.0%
Gross Profit TTM
17.8M
EBITDA
-144.6M
Diluted Eps TTM
-3.14
Quarterly Earnings Growth YOY
0.0
EPS Estimate Current Year
-1.85
EPS Estimate Next Year
-1.3
EPS Estimate Current Quarter
-0.45
EPS Estimate Next Quarter
-0.37

Analyst Recommendation

Buy
    68%Buy
    25%Hold
    6%Sell
Based on 16 Wall street analysts offering stock ratings for Outset Medical Inc(by analysts ranked 0 to 5 stars)
Based on 16 analyst
  • Current
  • 1M Ago
  • 3M Ago
Buy
11
9
9
Hold
4
5
5
Sell
1
1
1

Analyst Forecast

What analysts predicted

Upside of 485.48%

Current $0.62
Target $3.63

Company Financials

FY18Y/Y Change
Revenue
2.0M
-
Net Income
-49.8M
-
Net Profit Margin
-2.5K%
-
FY19Y/Y Change
Revenue
15.1M
↑ 651.27%
Net Income
-68.3M
↑ 37.2%
Net Profit Margin
-452.97%
↑ 2027.35%
FY20Y/Y Change
Revenue
49.9M
↑ 231.18%
Net Income
-120.7M
↑ 76.72%
Net Profit Margin
-241.71%
↑ 211.26%
FY21Y/Y Change
Revenue
102.6M
↑ 105.47%
Net Income
-131.9M
↑ 9.31%
Net Profit Margin
-128.59%
↑ 113.12%
FY22Y/Y Change
Revenue
115.4M
↑ 12.45%
Net Income
-163.0M
↑ 23.51%
Net Profit Margin
-141.24%
↓ 12.65%
FY23Y/Y Change
Revenue
130.4M
↑ 13.0%
Net Income
-172.8M
↑ 6.04%
Net Profit Margin
-132.54%
↑ 8.7%
Q1 FY23Q/Q Change
Revenue
33.5M
↑ 4.56%
Net Income
-44.0M
↑ 6.1%
Net Profit Margin
-131.39%
↓ 1.91%
Q2 FY23Q/Q Change
Revenue
36.0M
↑ 7.69%
Net Income
-44.0M
↑ 0.17%
Net Profit Margin
-122.21%
↑ 9.18%
Q3 FY23Q/Q Change
Revenue
30.4M
↓ 15.75%
Net Income
-46.2M
↑ 4.84%
Net Profit Margin
-152.1%
↓ 29.89%
Q4 FY23Q/Q Change
Revenue
30.5M
↑ 0.48%
Net Income
-38.6M
↓ 16.41%
Net Profit Margin
-126.53%
↑ 25.57%
Q1 FY24Q/Q Change
Revenue
28.2M
↓ 7.67%
Net Income
-39.9M
↑ 3.48%
Net Profit Margin
-141.81%
↓ 15.28%
Q2 FY24Q/Q Change
Revenue
27.4M
↓ 2.77%
Net Income
-34.5M
↓ 13.74%
Net Profit Margin
-125.8%
↑ 16.01%
FY18Y/Y Change
Total Assets
151.1M
-
Total Liabilities
439.1M
-
FY19Y/Y Change
Total Assets
88.4M
↓ 41.53%
Total Liabilities
460.6M
↑ 4.89%
FY20Y/Y Change
Total Assets
403.8M
↑ 357.0%
Total Liabilities
75.2M
↓ 83.67%
FY21Y/Y Change
Total Assets
463.5M
↑ 14.77%
Total Liabilities
89.4M
↑ 18.83%
FY22Y/Y Change
Total Assets
400.1M
↓ 13.67%
Total Liabilities
154.1M
↑ 72.43%
FY23Y/Y Change
Total Assets
313.8M
↓ 21.57%
Total Liabilities
190.9M
↑ 23.87%
Q1 FY23Q/Q Change
Total Assets
362.7M
↓ 9.36%
Total Liabilities
146.4M
↓ 5.03%
Q2 FY23Q/Q Change
Total Assets
334.4M
↓ 7.78%
Total Liabilities
151.3M
↑ 3.39%
Q3 FY23Q/Q Change
Total Assets
307.6M
↓ 8.04%
Total Liabilities
155.5M
↑ 2.74%
Q4 FY23Q/Q Change
Total Assets
313.8M
↑ 2.03%
Total Liabilities
190.9M
↑ 22.78%
Q1 FY24Q/Q Change
Total Assets
346.2M
↑ 10.34%
Total Liabilities
253.0M
↑ 32.54%
Q2 FY24Q/Q Change
Total Assets
314.5M
↓ 9.16%
Total Liabilities
245.9M
↓ 2.81%
FY18Y/Y Change
Operating Cash Flow
-46.4M
-
Investing Cash Flow
-68.8M
-
Financing Cash Flow
134.9M
-
FY19Y/Y Change
Operating Cash Flow
-70.3M
↑ 51.35%
Investing Cash Flow
74.3M
↓ 208.03%
Financing Cash Flow
249.0K
↓ 99.82%
FY20Y/Y Change
Operating Cash Flow
-99.0M
↑ 40.86%
Investing Cash Flow
3.9M
↓ 94.69%
Financing Cash Flow
385.7M
↑ 154792.37%
FY21Y/Y Change
Operating Cash Flow
-130.3M
↑ 31.56%
Investing Cash Flow
-142.5M
↓ 3710.51%
Financing Cash Flow
160.1M
↓ 58.48%
FY22Y/Y Change
Operating Cash Flow
-145.7M
↑ 11.87%
Investing Cash Flow
-66.3M
↓ 53.48%
Financing Cash Flow
72.9M
↓ 54.48%
Q1 FY23Q/Q Change
Operating Cash Flow
-44.8M
↑ 29.7%
Investing Cash Flow
2.6M
↓ 105.11%
Financing Cash Flow
5.3M
↓ 91.96%

Technicals Summary

Sell

Neutral

Buy

Outset Medical Inc is currently not in a favorable trading position ( SELL ) according to technical analysis indicators.

More on Technical Analysis

Peers

Company Name1 Month6 Month1 Year3 Years5 Years
Outset Medical Inc
Outset Medical Inc
25.86%
-75.45%
-93.5%
-98.75%
-98.98%
Stryker Corporation
Stryker Corporation
-3.08%
0.42%
31.64%
32.06%
64.94%
Boston Scientific Corp.
Boston Scientific Corp.
2.29%
23.07%
61.34%
93.81%
109.52%
Edwards Lifesciences Corp.
Edwards Lifesciences Corp.
-0.33%
-29.08%
-10.16%
-40.94%
-12.75%
Abbott Laboratories
Abbott Laboratories
-3.26%
1.92%
16.41%
-4.47%
38.99%
Medtronic Plc
Medtronic Plc
-2.6%
6.45%
17.48%
-30.41%
-17.71%
Company NameP/E RatioP/B RatioPEG RatioEPSROEROADiv YieldBVPS
Outset Medical Inc
Outset Medical Inc
NA
NA
NA
-1.85
-1.26
-0.29
NA
1.32
Stryker Corporation
Stryker Corporation
39.2
39.2
2.58
12.0
0.19
0.07
0.01
51.86
Boston Scientific Corp.
Boston Scientific Corp.
68.73
68.73
2.08
2.41
0.09
0.05
NA
13.85
Edwards Lifesciences Corp.
Edwards Lifesciences Corp.
25.78
25.78
3.46
2.62
0.22
0.12
NA
12.35
Abbott Laboratories
Abbott Laboratories
35.53
35.53
4.11
4.66
0.14
0.06
0.02
22.6
Medtronic Plc
Medtronic Plc
30.31
30.31
1.67
5.2
0.08
0.04
0.03
37.39
Company NameAnalyst ViewMarket Cap5 Years Return %PE RatioProfit Margin
Outset Medical Inc
Outset Medical Inc
Buy
$32.3M
-98.98%
NA
-136.72%
Stryker Corporation
Stryker Corporation
Buy
$133.8B
64.94%
39.2
16.12%
Boston Scientific Corp.
Boston Scientific Corp.
Buy
$124.5B
109.52%
68.73
12.0%
Edwards Lifesciences Corp.
Edwards Lifesciences Corp.
Buy
$39.5B
-12.75%
25.78
23.74%
Abbott Laboratories
Abbott Laboratories
Buy
$196.0B
38.99%
35.53
13.65%
Medtronic Plc
Medtronic Plc
Buy
$115.5B
-17.71%
30.31
12.06%

Insights on Outset Medical Inc

  • Decreasing Revenue

    Revenue is down for the last 3 quarters, 30.50M → 27.38M (in $), with an average decrease of 5.2% per quarter

  • Increasing Net Profit

    Netprofit is up for the last 2 quarters, -39.94M → -34.45M (in $), with an average increase of 15.9% per quarter

  • Vs BSX

    In the last 1 year, Boston Scientific Corp. has given 62.2% return, outperforming this stock by 156.0%

  • Vs BSX

    In the last 3 years, Boston Scientific Corp. has given 93.8% return, outperforming this stock by 192.6%

Institutional Holdings

  • FMR Inc

    14.78%

  • Ameriprise Financial Inc

    9.98%

  • Morgan Stanley - Brokerage Accounts

    7.32%

  • JPMorgan Chase & Co

    5.90%

  • Vanguard Group Inc

    5.08%

  • Millennium Management LLC

    3.73%

Company Information

outset is a pioneering medical technology company that always puts the patient before the machine. our human-centered model is designed to dramatically improve not only the care experience – for patients, families, providers and physicians alike – but also cost-efficiencies for providers. and to achieve this goal, we brought together the most dedicated, creative minds from dialysis with the most dedicated, creative minds from other healthcare fields, in the belief that cross-fertilization – along with hard work – is the surest path to invention. because we believe a dialysis machine should be as easy to use as an everyday consumer product, tablo was designed with simplicity in mind. one example is tablo’s touchscreen display, which offers step-by-step pictures and conversational instructions that make it hard to mess up no matter how new a patient, or caregiver, may be to dialysis. and with simplicity comes speed. we’ve set out to give people their time back. tablo dramatically reduces

Organization
Outset Medical Inc
Employees
480
CEO
Ms. Leslie L. Trigg
Industry
Health Technology

Discover More

FAQs